{"ticker": {"uuid": "5af1f9c4-6052-4fe7-80ab-024b91697514", "symbol": "IONS", "name": "Ionis Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ionis Pharmaceuticals (IONS) Proxy filing Summary", "summary": "Ionis Pharmaceuticals (IONS) has released its proxy filing summary for its annual meeting scheduled for June 4, 2026. Key proposals include the election of two directors, an advisory vote on executive compensation, and amendments to the 2011 Equity Incentive Plan and the 2000 Emp", "url": "https://quartr.com/events/ionis-pharmaceuticals-ions-proxy-filing_ofYVnSLK", "source_name": "Quartr", "published_at": "2026-07-19T03:11:08", "published_display": "19 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) director receives 5,220 shares on RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSmp5TmE5cG1ZZV9abmgyUGNVOXFOM3cwcjlhcnhpd0JSN254S1kzaW12YUVYRmR1OGJ0ejhzZjBsM04taDZKV05idTY0dnlSSHRUT3k0eVR1VjZfakxLaEJ3OFJQRHpUYUJkZzNhODBoc1kxdGxWY01Md2tia2ZTYThseFJrNkJJTTZ6QkZjRnVLei10eUV2Mm5UUTVidXZGSVRxTTNSU3YzMDJaM2JraFlhSzhfX2NNRTBF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:13:07+00:00", "published_display": "17 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) director receives 5,220 shares from RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbHJ6MllnV084VUlDRjJjYy1mQ0NaeGVGWGlDdlJrSEpUWm43U3FobjkwX1pEZWJacDdHRmR4Skk3Y3lQdEtxN3RBNXBEbFpmU2R2SGJwdFdnNjhjd0w2RzlfMmZ1WnRZRGpLWUxLU1FheGh5amtXRHVueURVRGU5ZEplYlRKYmltUlhLaVZSd2hQQkpWd1JQZEFZdjVaSU5POUNXZlBjcmFOdUJwNVNva2FXQlR4Nll3YW5B?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:12:58+00:00", "published_display": "17 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Ionis Pharmaceuticals Inc (IONS) on July 17th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securi", "url": "https://ng.investing.com/news/stock-market-news/form-4-ionis-pharmaceuticals-inc-for-17-july-93CH-2605802", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T22:09:33", "published_display": "17 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) awards 3,399 RSUs to board director Reikes", "summary": "Ionis Pharmaceuticals Inc. (IONS) has granted 3,399 Restricted Stock Units (RSUs) to its board director, Peter N Reikes, as revealed in a recent Form 4 filing. These RSUs are part of the company's Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and will vest i", "url": "https://www.stocktitan.net/sec-filings/IONS/form-4-ionis-pharmaceuticals-inc-insider-trading-activity-73acaf2bff7b.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:41:38", "published_display": "17 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity", "summary": "Ionis Pharmaceuticals director Ludwig Hantson reported a transaction in a Form 4 filing, acquiring 3,399 Restricted Stock Units (RSUs) on July 15, 2026. These RSUs, granted under the company's 2002 Non-Employee Directors' Stock Option Plan, will vest in three equal annual install", "url": "https://www.stocktitan.net/sec-filings/IONS/form-4-ionis-pharmaceuticals-inc-insider-trading-activity-335813c8a719.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:41:37", "published_display": "17 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7-Day Sell-Off Sends Ionis Pharmaceuticals Stock Down 37%", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWjdLbnNjUGh3STEyemJOTGNWOG04N1BrU0Zlcm1fYXdZYWgtMm05eThrT3RLYUx3blJTZXBrNlBNUnFTbFBCRUZMUVFRZWtNekpWMWZQSnBRU1BFczJJU2JFb0RNNnd1UjVQQ3lnOFRRZ1JjRG5XLVk3aTd2VkJ6Z0J2b29lbWtQc1lCb1dFMDVxZlI1aTlpclVaUzJLUF93djE5RVFKNHBOcXc3SGZGcGNBd3dTN2pmaVI0OW9EX0t1XzZpMVE?oc=5", "source_name": "Trefis", "published_at": "2026-07-17T11:34:04+00:00", "published_display": "17 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 37% Over 7 Straight Down Days", "summary": "Ionis Pharmaceuticals (IONS) stock has experienced a significant downturn, sliding 37% over seven consecutive trading days, resulting in a $5.2 billion loss in market value. This decline, which is specific to the company and not the broader market, is being attributed to the biot", "url": "https://www.trefis.com/stock/ions/articles/607725/ionis-pharmaceuticals-stock-slides-37-over-7-straight-down-days/2026-07-17", "source_name": "Trefis", "published_at": "2026-07-17T11:40:01", "published_display": "17 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOMHZyX2ZVNlNEVVdOdks4TGhnc0RrUG9QV0hYSGZ1Y1BoQy1oSXo0X2dMNnl5c1lEZ0poQVNURkVvcUxyZGVlRGFjNXQ4eDRWVno4UU9OMUhJZUtKMlFvZW5XeDdMTDhTTFJyVkVPREtHbEVERHQ0ZERNSFJwaml4dlF2dmxDckNzdDdObElpdDlJdFU1RjJXd3ctVWk3V1d4a2FJYjVxWQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T22:09:36+00:00", "published_display": "16 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS", "summary": "Pomerantz LLP is investigating Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following a significant stock drop. This investigation stems from the failure of their late-stage Phase-3 CARDIO-TTransform trial for Wainua to meet its primary endpoint, leading to a 23.9% share price decr", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc---ions-302826117.html", "source_name": "PR Newswire", "published_at": "2026-07-16T14:12:18", "published_display": "16 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 37% Over 6 Straight Down Days", "summary": "Ionis Pharmaceuticals' (IONS) stock has fallen 36.6% over six consecutive trading days, reducing its market value by $5.2 billion to $9.0 billion. The biotech company shows operational strains with a -33.3% operating margin over the last twelve months, significantly lower than th", "url": "https://www.trefis.com/stock/ions/articles/607503/ionis-pharmaceuticals-stock-slides-37-over-6-straight-down-days/2026-07-16", "source_name": "Trefis", "published_at": "2026-07-16T11:12:18", "published_display": "16 Jul 2026 11:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Ionis Pharmaceuticals, Inc. (IONS) following a significant drop in its stock price. This decline occurred after Ionis disclosed that its late-stage Phase-3 CARDIO-TTransform trial for ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1190974", "source_name": "ACCESS Newswire", "published_at": "2026-07-16T11:00:00", "published_display": "16 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research downgrades Ionis Pharmaceuticals stock rating", "summary": "Wolfe Research downgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Peerperform, citing an overvalued stock price based on Fair Value calculations and potential risks related to competitor success and pipeline stagnation. Despite maintaining a consensus \"Buy\" rating ", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-downgrades-ionis-pharmaceuticals-stock-rating-93CH-4794757", "source_name": "Investing.com", "published_at": "2026-07-16T07:12:18", "published_display": "16 Jul 2026 07:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood\u2019s ARK sells AMD stock, buys Circle Internet Group and Ionis", "summary": "Cathie Wood's ARK ETFs made significant portfolio adjustments on July 15, 2026. The firm notably purchased 220,012 shares of Circle Internet Group (CRCL) and 49,003 shares of Ionis Pharmaceuticals (IONS), while divesting 9,742 shares of Advanced Micro Devices (AMD) and continuing", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-amd-stock-buys-circle-internet-group-and-ionis-93CH-4793019", "source_name": "Investing.com", "published_at": "2026-07-15T14:42:04", "published_display": "15 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) to Discuss Q2 2026 Financial Performance in Live Webinar", "summary": "Ionis Pharmaceuticals (IONS) will host a live webinar on July 15, 2026, to discuss its Q2 2026 financial results. The company, known for its RNA-targeted therapies, is currently considered about 2.4% overvalued by GuruFocus, with a GF Score of 72/100 indicating strong growth and ", "url": "https://www.gurufocus.com/news/8960186/ionis-pharmaceuticals-ions-to-discuss-q2-2026-financial-performance-in-live-webinar", "source_name": "GuruFocus", "published_at": "2026-07-15T13:42:04", "published_display": "15 Jul 2026 13:42", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 36% Over 5 Straight Down Days", "summary": "Ionis Pharmaceuticals (IONS) stock has experienced a significant 36.4% cumulative loss over five consecutive trading days, wiping out $5.2 billion from its market value. Despite 47.5% revenue growth over the last twelve months, the biotech company struggles with profitability, sh", "url": "https://www.trefis.com/stock/ions/articles/607306/ionis-pharmaceuticals-stock-slides-36-over-5-straight-down-days/2026-07-15", "source_name": "Trefis", "published_at": "2026-07-15T13:42:03", "published_display": "15 Jul 2026 13:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis to hold second quarter 2026 financial results webcast", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-hold-second-quarter-2026-110500932.html", "source_name": "Business Wire", "published_at": "2026-07-15T11:05:00+00:00", "published_display": "15 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis to discuss second-quarter results on July 29 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdjlsSElPTGMxdWJRcUVzQkxCUUVNT0I2Y1lid1FUaHRHNms4d1ljdnZILXh3TW5tbEFydV9JZEI2Z2dxRERfZ3BTcE1QS3FpTWFnMlczM19kYkR6NkVqMDM2TnBHcURIaEpWQmZoakxOVEJ5WW9iLVJOazU4OVBWUnRhaTFNWGlIREdzZG52REFRa2xNeGE5bHdqUm9BT0t6UzllZVRRN3BYUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:05:00+00:00", "published_display": "15 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz investigates Ionis Pharmaceuticals after trial failure causes 24% stock drop", "summary": "Pomerantz LLP is investigating Ionis Pharmaceuticals following a 23.9% stock drop caused by the failure of its Phase-3 CARDIO-TTransform trial for Wainua. The law firm is looking into potential securities fraud or other unlawful practices by Ionis and its officers. Affected inves", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-ionis-pharmaceuticals", "source_name": "Pluang", "published_at": "2026-07-14T22:45:41", "published_display": "14 Jul 2026 22:45", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS | FinancialContent", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals, Inc. (IONS) after the company announced its Phase-3 CARDIO-TTransform trial for Wainua failed to meet its primary endpoint. This news led to a significant 23.9% drop in Ionis's stock p", "url": "https://www.financialcontent.com/article/gnwcq-2026-7-14-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc-ions", "source_name": "FinancialContent", "published_at": "2026-07-14T20:45:41", "published_display": "14 Jul 2026 20:45", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS", "summary": "Ionis Pharmaceuticals (IONS) experienced a 23% stock drop after its late-stage trial for an experimental heart disease therapy, eplontersen, failed to meet its primary efficacy endpoint. This unexpected outcome has led the firm Hagens Berman to investigate whether Ionis was suffi", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327167/0/en/Ionis-Pharmaceuticals-Inc-IONS-Faces-Investor-Scrutiny-After-Surprise-Trial-Failure-Drives-Stock-Down-23-HBSS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T18:42:03", "published_display": "14 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-partner-biogen-presents-phase-131600404.html", "source_name": "Business Wire", "published_at": "2026-07-14T13:16:00+00:00", "published_display": "14 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An investigational Alzheimer\u2019s drug shows 50% slower decline on a cognition measure", "summary": "Ionis Pharmaceuticals' partner, Biogen, presented Phase 2 CELIA data for diranersen, an investigational antisense oligonucleotide therapy for early Alzheimer\u2019s disease. The study demonstrated meaningful clinical efficacy, with the 60 mg dose showing a 50% slower decline on the MM", "url": "https://www.stocktitan.net/news/IONS/ionis-partner-biogen-presents-phase-2-celia-data-at-aaic-2wroulfcvkvx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:41:57", "published_display": "14 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Begins Dosing in Phase I/II Dravet Syndrome Study", "summary": "Ionis Pharmaceuticals (IONS) has commenced dosing the first patient in its phase I/II ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. This marks an important step in developing a potential disease-modifying treatment for the rare neurologica", "url": "https://finance.yahoo.com/healthcare/articles/ionis-begins-dosing-phase-ii-140400893.html", "source_name": "Market source", "published_at": "2026-07-14T13:41:57", "published_display": "14 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US462222AG5 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the US462222AG5 bond issued by Ionis Pharmaceuticals, Inc. It details the bond's issue date, maturity date, outstanding amount, face value, and coupon rate. The company profile highlights its focus on developing therapeutic drugs using antise", "url": "https://www.tradingview.com/symbols/FWB-US462222AG5/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T00:40:59", "published_display": "14 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome", "summary": "Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an RNA-targeted medicine for Dravet syndrome. ION337, developed with Ionis' advanced NMA technology, aims to be a disease-modifying therapy by increasing NaV1.1 protein production and ", "url": "https://www.biospace.com/press-releases/ionis-doses-first-participant-in-phase-1-2-ascend-study-of-ion337-in-dravet-syndrome", "source_name": "BioSpace", "published_at": "2026-07-13T16:12:06", "published_display": "13 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis starts Dravet syndrome drug trial", "summary": "Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. The trial will evaluate the drug's safety, tolerability, and dosing in children aged 2 to 12 years. ION337 utilizes Ionis'", "url": "https://grafa.com/en/news/united-states/ionis-ion337-dravet-syndrome-ascend-trial", "source_name": "grafa.com", "published_at": "2026-07-13T15:40:59", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS Maintained by RBC Capital -- Price Target Lowered to $85.00", "summary": "RBC Capital has maintained an \"Outperform\" rating for Ionis Pharmaceuticals (IONS) but lowered its price target from $100.00 to $85.00, reflecting a cautious outlook. The company's GF Value\u2122 suggests it is currently 6.7% overvalued, while its GF Score\u2122 of 72/100 indicates solid p", "url": "https://www.gurufocus.com/news/8955654/ions-maintained-by-rbc-capital-price-target-lowered-to-8500", "source_name": "GuruFocus", "published_at": "2026-07-13T15:12:06", "published_display": "13 Jul 2026 15:12", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcXhFWFc2TVMwSFNRSHhOQlZtWUNab3lPanhBVlR2Y19vNnNuanRna2trMVJrbktwUUhvb3hfcEhGZHd3TlJ5dlBPb1dvRXpaRWZHVG81NnpfMUFCNlNaS00xcDBsV01DVXZQdnAtQkk2TlNRek91MFcxMVMzSU9Ga0kxdktCckplU2RSdnJjZzRuQl9kb0Y5bXE0SDlhUXZDSVlzVDB4eFhLdHlrR1ZtcEZOZUJKMHdqM2pVZ2p4Z0kxbmtqaHU5b21WZ21PNTZ0QjZIT0p3cHAxLVR1bG9tSlVrMjI5b3NSVGhiaVp5S0djSTZO?oc=5", "source_name": "Business Wire", "published_at": "2026-07-13T14:00:00+00:00", "published_display": "13 Jul 2026 14:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ionis Doses First Participant in Phase 1-2 Trial of Dravet Syndrome Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-doses-first-participant-phase-115446526.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:54:46+00:00", "published_display": "13 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating", "summary": "RBC Capital Markets has reduced its price target for Ionis Pharmaceuticals (IONS) to $85 from $100, while maintaining an Outperform rating on the stock. This adjustment reflects a revised valuation perspective for the biotechnology company.", "url": "https://www.moomoo.com/news/post/72855062/rbc-cuts-price-target-on-ionis-pharmaceuticals-to-85-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T11:40:59", "published_display": "13 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Ionis RNA drug ION337 enters first human test in Dravet syndrome", "summary": "Ionis Pharmaceuticals has initiated its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome, a severe neurological disorder. This marks the first human participant dosed with ION337, which utilizes Ionis' advanced NMA technology designe", "url": "https://www.stocktitan.net/news/IONS/ionis-doses-first-participant-in-phase-1-2-ascend-study-of-ion337-in-3i00iwd8nifi.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:12:06", "published_display": "13 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Faces A Key Setback As Eplontersen Misses In Phase 3", "summary": "Ionis Pharmaceuticals and AstraZeneca announced that their Phase 3 trial for eplontersen in transthyretin mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, posing a significant setback for one of Ionis's key late-stage programs. Although the trial showed", "url": "https://www.sahmcapital.com/news/content/ionis-pharmaceuticals-ions-faces-a-key-setback-as-eplontersen-misses-in-phase-3-2026-07-11", "source_name": "Sahm", "published_at": "2026-07-12T19:12:18", "published_display": "12 Jul 2026 19:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Status Update Summary", "summary": "Ionis Pharmaceuticals (IONS) has transitioned from a partner-focused model to a fully integrated commercial-stage biotech, emphasizing independent drug launches and commercialization. The company has achieved three transformational medicine approvals, including Tryngolza, and has", "url": "https://quartr.com/events/ionis-pharmaceuticals-ions-status-update_ofYVqwDh", "source_name": "Quartr", "published_at": "2026-07-10T22:39:47", "published_display": "10 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up", "summary": "Ionis Pharmaceuticals (IONS) experienced a significant intraday drop of 9%, bringing its weekly decline to over 25%, following the failure of its Phase 3 CARDIO-TTRansform study for eplontersen. This clinical setback for a key value driver negatively impacted the company and its ", "url": "https://247wallst.com/investing/2026/07/10/ionis-pharmaceuticals-drops-another-9-as-bad-news-piles-up/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T17:37:00", "published_display": "10 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain", "summary": "Ionis Pharmaceuticals and AstraZeneca's Phase 3 CARDIO-TTRansform study for eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint. The trial's failure, where adding eplontersen did not significantly improve outcomes ov", "url": "https://www.benzinga.com/news/health-care/26/07/60390366/ionis-astrazeneca-stumble-in-attr-cm-trial-as-rivals-stand-to-gain", "source_name": "Benzinga", "published_at": "2026-07-10T15:09:43", "published_display": "10 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQSW9HZHljRTV1elNtemVmNjJkWDBOSG95b1VOT0VSaFA3Y19UQlZFeFd2TzRrZnRuYTJLd3pfb3FCMVF3ckk2Nlh0TjRpVUJHVi0yOGtIUkFWeWFfMUJjLVp5Mk9VdWVxY1htQ0lkN0YxUlNiX2I5em5VT1prOVh5ZjAzblVVd1hBancyem5SZ0RvT2NRektNNHZqWmpZWnlSVXpvbGhrWExmbFFINEJILWlQZElwNmpyVkxwY0UteVVrdXd0d3NkQjVzM1BsX1pmcnpPX3E3OEE4UkFqQkpNeVdIZW5jWHMtM1Y1Y19KdzdDUVNCaTNQRXZYbm82NlhNWExJbDlDblg4SHFHaUJZaQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:00:00+00:00", "published_display": "10 Jul 2026 13:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Long Climb Back For Ionis Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOVUdaeFhRTFRrcU5kV09Ba1NzN3pCX09GcHhHd2dxX2Y0ZThYdG5pdVhUYk9oRmtNdEJaWnNfM3VJR0tlZVBMcW5LQjF3cFBPVG1ZVm9KR3JTMEViNGlQdnlycGVIUE4xMGJYNVoyM0pjU1VtMG1DbDRKUGJpOGw0ckVEVkt5MFA1ZU9mNll6ODJzNlJYa1B2SnpxMWo?oc=5", "source_name": "Trefis", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ionis Pharmaceuticals (IONS) Is Up 6.7% After Angelman Phase 3 Pediatric Enrollment Milestone And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca and Ionis Stock Slump After Trial Miss Is an Overreaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQU3Zla2lxdExtVXVweTBJclR3MldqOXN4bV8zZ0RIa1c2Q0ZDRng4Sm5SVHhvS2dJYUpCR2ZiMmUxcVVmMFhIeGZsUmpwTW81MURLUUJPVVZoSWRRZG5aOHpIWmw4MGNxbXJUMnk0Q0Q2T3NLRDY3MVVrMTdyT1ctOE5vaDFSZVMzVHlYaVNLVFM?oc=5", "source_name": "Barron's", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ionis Pharmaceuticals, Inc. (IONS) Stock a Buy After Tryngolza\u2019s FDA Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOT3pjWVhlN1Baa3g1OEZqcW9pMjhFbjVFLUkwVTcyNHIyV1F2aVdfc0lVaGpEM1c1OGd6UlJTQmVLN3V3ZkxHQXpWUEEwV3lYSmVWdjcwQVBUZkIzcTRTaDFzQTBvaG13RHhIM2xIRGxUYkVDaHRJVHRsX3BRU3lpUDViLUxqYW1kT2cxRnU3LXk4a1JLaHZOdWhmSFVxdw?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IONIS PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQS1paY2pfZXhpYnphMnpKTEdzZzdwZ1JqeGxGNFdCTTZMWVpNdm1ZX0J2ZXowaUxick5oelZiY05RSXpMb1VlV0oyak1OeWRVcGVSZGdnX3dKT241QWhiQm84bmVIRXNhZ2VjX2d2NzlMZGRuT0F0S2pMZUN5QWpCQVNtcy1Sem1zQUpvck54VUFXQmJJSkp3TTktRmdLSkJvQjJIOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T20:41:28+00:00", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis: FDA Label Expansion of Tryngolza Expands Commercial Opportunity; Shares Undervalued", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOWWdUblR3dG5VbUw0WG5oMm1LVU43R2VVc0FnckppR29EM3BORlhid0M1ZUk2VVBUVk83NUt3Sm91QjFVYVVPaFdIdjhfTmtqbjFVU3lpd0pPcDNlTmctdl9tZGpCc2djLW9kRFAwbFlNWVNQeFVmWHhMYXc1WUdVeDJacEVwQWNEci14Y3FCREhSQ01BSWFvYjUwN3l1b3RjbHpXTE93ZS0wWWwtdE9FS0lOaUhVWTRtemd3T1l2c3hCSlAxRUJ4Q0hTcW03U29PcllTTm9qQQ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis hands rare-disease drug zilganersen rights outside the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUzg1VTY4RXJHd2ZfcW4zemxVaHpjSGxlQUplbG9jVm9BSnZUODFUM1QzdmJaVV96RlpzRGpRWWRRZU14aXByaU1VdlRRa3BuQ29NeHhUcHg2NUZtUkw0eTNYdnV0RFNVM24tbHZfTnpWeG1fc2xsYkFtNmppMDRPeXY2eTdKd2U5Tl95SU91YlQ1TXNxSWVTQkRIWkhsRkl1STg3YjhDMVB3aDdNTVVYS3NIUWhmRlVMa2RkNU1kYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Trailing US$381.4m Loss Tests Bullish Profitability Narratives Ahead Of Q1 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Ionis Pharmaceuticals (IONS) After A 150% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Ionis Pharmaceuticals (IONS) Proxy filing Summary", "summary": "Ionis Pharmaceuticals (IONS) has released its proxy filing summary for its annual meeting scheduled for June 4, 2026. Key proposals include the election of two directors, an advisory vote on executive compensation, and amendments to the 2011 Equity Incentive Plan and the 2000 Emp", "url": "https://quartr.com/events/ionis-pharmaceuticals-ions-proxy-filing_ofYVnSLK", "source_name": "Quartr", "published_at": "2026-07-19T03:11:08", "published_display": "19 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) director receives 5,220 shares on RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSmp5TmE5cG1ZZV9abmgyUGNVOXFOM3cwcjlhcnhpd0JSN254S1kzaW12YUVYRmR1OGJ0ejhzZjBsM04taDZKV05idTY0dnlSSHRUT3k0eVR1VjZfakxLaEJ3OFJQRHpUYUJkZzNhODBoc1kxdGxWY01Md2tia2ZTYThseFJrNkJJTTZ6QkZjRnVLei10eUV2Mm5UUTVidXZGSVRxTTNSU3YzMDJaM2JraFlhSzhfX2NNRTBF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:13:07+00:00", "published_display": "17 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) director receives 5,220 shares from RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbHJ6MllnV084VUlDRjJjYy1mQ0NaeGVGWGlDdlJrSEpUWm43U3FobjkwX1pEZWJacDdHRmR4Skk3Y3lQdEtxN3RBNXBEbFpmU2R2SGJwdFdnNjhjd0w2RzlfMmZ1WnRZRGpLWUxLU1FheGh5amtXRHVueURVRGU5ZEplYlRKYmltUlhLaVZSd2hQQkpWd1JQZEFZdjVaSU5POUNXZlBjcmFOdUJwNVNva2FXQlR4Nll3YW5B?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:12:58+00:00", "published_display": "17 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Ionis Pharmaceuticals Inc (IONS) on July 17th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securi", "url": "https://ng.investing.com/news/stock-market-news/form-4-ionis-pharmaceuticals-inc-for-17-july-93CH-2605802", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T22:09:33", "published_display": "17 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) awards 3,399 RSUs to board director Reikes", "summary": "Ionis Pharmaceuticals Inc. (IONS) has granted 3,399 Restricted Stock Units (RSUs) to its board director, Peter N Reikes, as revealed in a recent Form 4 filing. These RSUs are part of the company's Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and will vest i", "url": "https://www.stocktitan.net/sec-filings/IONS/form-4-ionis-pharmaceuticals-inc-insider-trading-activity-73acaf2bff7b.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:41:38", "published_display": "17 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity", "summary": "Ionis Pharmaceuticals director Ludwig Hantson reported a transaction in a Form 4 filing, acquiring 3,399 Restricted Stock Units (RSUs) on July 15, 2026. These RSUs, granted under the company's 2002 Non-Employee Directors' Stock Option Plan, will vest in three equal annual install", "url": "https://www.stocktitan.net/sec-filings/IONS/form-4-ionis-pharmaceuticals-inc-insider-trading-activity-335813c8a719.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:41:37", "published_display": "17 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7-Day Sell-Off Sends Ionis Pharmaceuticals Stock Down 37%", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWjdLbnNjUGh3STEyemJOTGNWOG04N1BrU0Zlcm1fYXdZYWgtMm05eThrT3RLYUx3blJTZXBrNlBNUnFTbFBCRUZMUVFRZWtNekpWMWZQSnBRU1BFczJJU2JFb0RNNnd1UjVQQ3lnOFRRZ1JjRG5XLVk3aTd2VkJ6Z0J2b29lbWtQc1lCb1dFMDVxZlI1aTlpclVaUzJLUF93djE5RVFKNHBOcXc3SGZGcGNBd3dTN2pmaVI0OW9EX0t1XzZpMVE?oc=5", "source_name": "Trefis", "published_at": "2026-07-17T11:34:04+00:00", "published_display": "17 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 37% Over 7 Straight Down Days", "summary": "Ionis Pharmaceuticals (IONS) stock has experienced a significant downturn, sliding 37% over seven consecutive trading days, resulting in a $5.2 billion loss in market value. This decline, which is specific to the company and not the broader market, is being attributed to the biot", "url": "https://www.trefis.com/stock/ions/articles/607725/ionis-pharmaceuticals-stock-slides-37-over-7-straight-down-days/2026-07-17", "source_name": "Trefis", "published_at": "2026-07-17T11:40:01", "published_display": "17 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOMHZyX2ZVNlNEVVdOdks4TGhnc0RrUG9QV0hYSGZ1Y1BoQy1oSXo0X2dMNnl5c1lEZ0poQVNURkVvcUxyZGVlRGFjNXQ4eDRWVno4UU9OMUhJZUtKMlFvZW5XeDdMTDhTTFJyVkVPREtHbEVERHQ0ZERNSFJwaml4dlF2dmxDckNzdDdObElpdDlJdFU1RjJXd3ctVWk3V1d4a2FJYjVxWQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T22:09:36+00:00", "published_display": "16 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS", "summary": "Pomerantz LLP is investigating Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following a significant stock drop. This investigation stems from the failure of their late-stage Phase-3 CARDIO-TTransform trial for Wainua to meet its primary endpoint, leading to a 23.9% share price decr", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc---ions-302826117.html", "source_name": "PR Newswire", "published_at": "2026-07-16T14:12:18", "published_display": "16 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 37% Over 6 Straight Down Days", "summary": "Ionis Pharmaceuticals' (IONS) stock has fallen 36.6% over six consecutive trading days, reducing its market value by $5.2 billion to $9.0 billion. The biotech company shows operational strains with a -33.3% operating margin over the last twelve months, significantly lower than th", "url": "https://www.trefis.com/stock/ions/articles/607503/ionis-pharmaceuticals-stock-slides-37-over-6-straight-down-days/2026-07-16", "source_name": "Trefis", "published_at": "2026-07-16T11:12:18", "published_display": "16 Jul 2026 11:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Ionis Pharmaceuticals, Inc. (IONS) following a significant drop in its stock price. This decline occurred after Ionis disclosed that its late-stage Phase-3 CARDIO-TTransform trial for ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1190974", "source_name": "ACCESS Newswire", "published_at": "2026-07-16T11:00:00", "published_display": "16 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research downgrades Ionis Pharmaceuticals stock rating", "summary": "Wolfe Research downgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Peerperform, citing an overvalued stock price based on Fair Value calculations and potential risks related to competitor success and pipeline stagnation. Despite maintaining a consensus \"Buy\" rating ", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-downgrades-ionis-pharmaceuticals-stock-rating-93CH-4794757", "source_name": "Investing.com", "published_at": "2026-07-16T07:12:18", "published_display": "16 Jul 2026 07:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood\u2019s ARK sells AMD stock, buys Circle Internet Group and Ionis", "summary": "Cathie Wood's ARK ETFs made significant portfolio adjustments on July 15, 2026. The firm notably purchased 220,012 shares of Circle Internet Group (CRCL) and 49,003 shares of Ionis Pharmaceuticals (IONS), while divesting 9,742 shares of Advanced Micro Devices (AMD) and continuing", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-amd-stock-buys-circle-internet-group-and-ionis-93CH-4793019", "source_name": "Investing.com", "published_at": "2026-07-15T14:42:04", "published_display": "15 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) to Discuss Q2 2026 Financial Performance in Live Webinar", "summary": "Ionis Pharmaceuticals (IONS) will host a live webinar on July 15, 2026, to discuss its Q2 2026 financial results. The company, known for its RNA-targeted therapies, is currently considered about 2.4% overvalued by GuruFocus, with a GF Score of 72/100 indicating strong growth and ", "url": "https://www.gurufocus.com/news/8960186/ionis-pharmaceuticals-ions-to-discuss-q2-2026-financial-performance-in-live-webinar", "source_name": "GuruFocus", "published_at": "2026-07-15T13:42:04", "published_display": "15 Jul 2026 13:42", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Stock Slides 36% Over 5 Straight Down Days", "summary": "Ionis Pharmaceuticals (IONS) stock has experienced a significant 36.4% cumulative loss over five consecutive trading days, wiping out $5.2 billion from its market value. Despite 47.5% revenue growth over the last twelve months, the biotech company struggles with profitability, sh", "url": "https://www.trefis.com/stock/ions/articles/607306/ionis-pharmaceuticals-stock-slides-36-over-5-straight-down-days/2026-07-15", "source_name": "Trefis", "published_at": "2026-07-15T13:42:03", "published_display": "15 Jul 2026 13:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis to hold second quarter 2026 financial results webcast", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-hold-second-quarter-2026-110500932.html", "source_name": "Business Wire", "published_at": "2026-07-15T11:05:00+00:00", "published_display": "15 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis to discuss second-quarter results on July 29 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdjlsSElPTGMxdWJRcUVzQkxCUUVNT0I2Y1lid1FUaHRHNms4d1ljdnZILXh3TW5tbEFydV9JZEI2Z2dxRERfZ3BTcE1QS3FpTWFnMlczM19kYkR6NkVqMDM2TnBHcURIaEpWQmZoakxOVEJ5WW9iLVJOazU4OVBWUnRhaTFNWGlIREdzZG52REFRa2xNeGE5bHdqUm9BT0t6UzllZVRRN3BYUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:05:00+00:00", "published_display": "15 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz investigates Ionis Pharmaceuticals after trial failure causes 24% stock drop", "summary": "Pomerantz LLP is investigating Ionis Pharmaceuticals following a 23.9% stock drop caused by the failure of its Phase-3 CARDIO-TTransform trial for Wainua. The law firm is looking into potential securities fraud or other unlawful practices by Ionis and its officers. Affected inves", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-ionis-pharmaceuticals", "source_name": "Pluang", "published_at": "2026-07-14T22:45:41", "published_display": "14 Jul 2026 22:45", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS | FinancialContent", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals, Inc. (IONS) after the company announced its Phase-3 CARDIO-TTransform trial for Wainua failed to meet its primary endpoint. This news led to a significant 23.9% drop in Ionis's stock p", "url": "https://www.financialcontent.com/article/gnwcq-2026-7-14-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc-ions", "source_name": "FinancialContent", "published_at": "2026-07-14T20:45:41", "published_display": "14 Jul 2026 20:45", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% \u2013 HBSS", "summary": "Ionis Pharmaceuticals (IONS) experienced a 23% stock drop after its late-stage trial for an experimental heart disease therapy, eplontersen, failed to meet its primary efficacy endpoint. This unexpected outcome has led the firm Hagens Berman to investigate whether Ionis was suffi", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327167/0/en/Ionis-Pharmaceuticals-Inc-IONS-Faces-Investor-Scrutiny-After-Surprise-Trial-Failure-Drives-Stock-Down-23-HBSS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T18:42:03", "published_display": "14 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-partner-biogen-presents-phase-131600404.html", "source_name": "Business Wire", "published_at": "2026-07-14T13:16:00+00:00", "published_display": "14 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An investigational Alzheimer\u2019s drug shows 50% slower decline on a cognition measure", "summary": "Ionis Pharmaceuticals' partner, Biogen, presented Phase 2 CELIA data for diranersen, an investigational antisense oligonucleotide therapy for early Alzheimer\u2019s disease. The study demonstrated meaningful clinical efficacy, with the 60 mg dose showing a 50% slower decline on the MM", "url": "https://www.stocktitan.net/news/IONS/ionis-partner-biogen-presents-phase-2-celia-data-at-aaic-2wroulfcvkvx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:41:57", "published_display": "14 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Begins Dosing in Phase I/II Dravet Syndrome Study", "summary": "Ionis Pharmaceuticals (IONS) has commenced dosing the first patient in its phase I/II ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. This marks an important step in developing a potential disease-modifying treatment for the rare neurologica", "url": "https://finance.yahoo.com/healthcare/articles/ionis-begins-dosing-phase-ii-140400893.html", "source_name": "Market source", "published_at": "2026-07-14T13:41:57", "published_display": "14 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US462222AG5 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the US462222AG5 bond issued by Ionis Pharmaceuticals, Inc. It details the bond's issue date, maturity date, outstanding amount, face value, and coupon rate. The company profile highlights its focus on developing therapeutic drugs using antise", "url": "https://www.tradingview.com/symbols/FWB-US462222AG5/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T00:40:59", "published_display": "14 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome", "summary": "Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an RNA-targeted medicine for Dravet syndrome. ION337, developed with Ionis' advanced NMA technology, aims to be a disease-modifying therapy by increasing NaV1.1 protein production and ", "url": "https://www.biospace.com/press-releases/ionis-doses-first-participant-in-phase-1-2-ascend-study-of-ion337-in-dravet-syndrome", "source_name": "BioSpace", "published_at": "2026-07-13T16:12:06", "published_display": "13 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis starts Dravet syndrome drug trial", "summary": "Ionis Pharmaceuticals has dosed the first participant in its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome. The trial will evaluate the drug's safety, tolerability, and dosing in children aged 2 to 12 years. ION337 utilizes Ionis'", "url": "https://grafa.com/en/news/united-states/ionis-ion337-dravet-syndrome-ascend-trial", "source_name": "grafa.com", "published_at": "2026-07-13T15:40:59", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS Maintained by RBC Capital -- Price Target Lowered to $85.00", "summary": "RBC Capital has maintained an \"Outperform\" rating for Ionis Pharmaceuticals (IONS) but lowered its price target from $100.00 to $85.00, reflecting a cautious outlook. The company's GF Value\u2122 suggests it is currently 6.7% overvalued, while its GF Score\u2122 of 72/100 indicates solid p", "url": "https://www.gurufocus.com/news/8955654/ions-maintained-by-rbc-capital-price-target-lowered-to-8500", "source_name": "GuruFocus", "published_at": "2026-07-13T15:12:06", "published_display": "13 Jul 2026 15:12", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcXhFWFc2TVMwSFNRSHhOQlZtWUNab3lPanhBVlR2Y19vNnNuanRna2trMVJrbktwUUhvb3hfcEhGZHd3TlJ5dlBPb1dvRXpaRWZHVG81NnpfMUFCNlNaS00xcDBsV01DVXZQdnAtQkk2TlNRek91MFcxMVMzSU9Ga0kxdktCckplU2RSdnJjZzRuQl9kb0Y5bXE0SDlhUXZDSVlzVDB4eFhLdHlrR1ZtcEZOZUJKMHdqM2pVZ2p4Z0kxbmtqaHU5b21WZ21PNTZ0QjZIT0p3cHAxLVR1bG9tSlVrMjI5b3NSVGhiaVp5S0djSTZO?oc=5", "source_name": "Business Wire", "published_at": "2026-07-13T14:00:00+00:00", "published_display": "13 Jul 2026 14:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Doses First Participant in Phase 1-2 Trial of Dravet Syndrome Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-doses-first-participant-phase-115446526.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:54:46+00:00", "published_display": "13 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating", "summary": "RBC Capital Markets has reduced its price target for Ionis Pharmaceuticals (IONS) to $85 from $100, while maintaining an Outperform rating on the stock. This adjustment reflects a revised valuation perspective for the biotechnology company.", "url": "https://www.moomoo.com/news/post/72855062/rbc-cuts-price-target-on-ionis-pharmaceuticals-to-85-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T11:40:59", "published_display": "13 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Ionis RNA drug ION337 enters first human test in Dravet syndrome", "summary": "Ionis Pharmaceuticals has initiated its Phase 1-2 ASCEND study for ION337, an investigational RNA-targeted medicine for Dravet syndrome, a severe neurological disorder. This marks the first human participant dosed with ION337, which utilizes Ionis' advanced NMA technology designe", "url": "https://www.stocktitan.net/news/IONS/ionis-doses-first-participant-in-phase-1-2-ascend-study-of-ion337-in-3i00iwd8nifi.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:12:06", "published_display": "13 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Faces A Key Setback As Eplontersen Misses In Phase 3", "summary": "Ionis Pharmaceuticals and AstraZeneca announced that their Phase 3 trial for eplontersen in transthyretin mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, posing a significant setback for one of Ionis's key late-stage programs. Although the trial showed", "url": "https://www.sahmcapital.com/news/content/ionis-pharmaceuticals-ions-faces-a-key-setback-as-eplontersen-misses-in-phase-3-2026-07-11", "source_name": "Sahm", "published_at": "2026-07-12T19:12:18", "published_display": "12 Jul 2026 19:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Status Update Summary", "summary": "Ionis Pharmaceuticals (IONS) has transitioned from a partner-focused model to a fully integrated commercial-stage biotech, emphasizing independent drug launches and commercialization. The company has achieved three transformational medicine approvals, including Tryngolza, and has", "url": "https://quartr.com/events/ionis-pharmaceuticals-ions-status-update_ofYVqwDh", "source_name": "Quartr", "published_at": "2026-07-10T22:39:47", "published_display": "10 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up", "summary": "Ionis Pharmaceuticals (IONS) experienced a significant intraday drop of 9%, bringing its weekly decline to over 25%, following the failure of its Phase 3 CARDIO-TTRansform study for eplontersen. This clinical setback for a key value driver negatively impacted the company and its ", "url": "https://247wallst.com/investing/2026/07/10/ionis-pharmaceuticals-drops-another-9-as-bad-news-piles-up/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T17:37:00", "published_display": "10 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain", "summary": "Ionis Pharmaceuticals and AstraZeneca's Phase 3 CARDIO-TTRansform study for eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint. The trial's failure, where adding eplontersen did not significantly improve outcomes ov", "url": "https://www.benzinga.com/news/health-care/26/07/60390366/ionis-astrazeneca-stumble-in-attr-cm-trial-as-rivals-stand-to-gain", "source_name": "Benzinga", "published_at": "2026-07-10T15:09:43", "published_display": "10 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQSW9HZHljRTV1elNtemVmNjJkWDBOSG95b1VOT0VSaFA3Y19UQlZFeFd2TzRrZnRuYTJLd3pfb3FCMVF3ckk2Nlh0TjRpVUJHVi0yOGtIUkFWeWFfMUJjLVp5Mk9VdWVxY1htQ0lkN0YxUlNiX2I5em5VT1prOVh5ZjAzblVVd1hBancyem5SZ0RvT2NRektNNHZqWmpZWnlSVXpvbGhrWExmbFFINEJILWlQZElwNmpyVkxwY0UteVVrdXd0d3NkQjVzM1BsX1pmcnpPX3E3OEE4UkFqQkpNeVdIZW5jWHMtM1Y1Y19KdzdDUVNCaTNQRXZYbm82NlhNWExJbDlDblg4SHFHaUJZaQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:00:00+00:00", "published_display": "10 Jul 2026 13:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Long Climb Back For Ionis Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOVUdaeFhRTFRrcU5kV09Ba1NzN3pCX09GcHhHd2dxX2Y0ZThYdG5pdVhUYk9oRmtNdEJaWnNfM3VJR0tlZVBMcW5LQjF3cFBPVG1ZVm9KR3JTMEViNGlQdnlycGVIUE4xMGJYNVoyM0pjU1VtMG1DbDRKUGJpOGw0ckVEVkt5MFA1ZU9mNll6ODJzNlJYa1B2SnpxMWo?oc=5", "source_name": "Trefis", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ionis Pharmaceuticals (IONS) Is Up 6.7% After Angelman Phase 3 Pediatric Enrollment Milestone And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca and Ionis Stock Slump After Trial Miss Is an Overreaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQU3Zla2lxdExtVXVweTBJclR3MldqOXN4bV8zZ0RIa1c2Q0ZDRng4Sm5SVHhvS2dJYUpCR2ZiMmUxcVVmMFhIeGZsUmpwTW81MURLUUJPVVZoSWRRZG5aOHpIWmw4MGNxbXJUMnk0Q0Q2T3NLRDY3MVVrMTdyT1ctOE5vaDFSZVMzVHlYaVNLVFM?oc=5", "source_name": "Barron's", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ionis Pharmaceuticals, Inc. (IONS) Stock a Buy After Tryngolza\u2019s FDA Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOT3pjWVhlN1Baa3g1OEZqcW9pMjhFbjVFLUkwVTcyNHIyV1F2aVdfc0lVaGpEM1c1OGd6UlJTQmVLN3V3ZkxHQXpWUEEwV3lYSmVWdjcwQVBUZkIzcTRTaDFzQTBvaG13RHhIM2xIRGxUYkVDaHRJVHRsX3BRU3lpUDViLUxqYW1kT2cxRnU3LXk4a1JLaHZOdWhmSFVxdw?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IONIS PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQS1paY2pfZXhpYnphMnpKTEdzZzdwZ1JqeGxGNFdCTTZMWVpNdm1ZX0J2ZXowaUxick5oelZiY05RSXpMb1VlV0oyak1OeWRVcGVSZGdnX3dKT241QWhiQm84bmVIRXNhZ2VjX2d2NzlMZGRuT0F0S2pMZUN5QWpCQVNtcy1Sem1zQUpvck54VUFXQmJJSkp3TTktRmdLSkJvQjJIOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T20:41:28+00:00", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPT2JKWW5WZFR5T2FPc29DcVJ1U2JKX0pyVXJTdWJLWXAxQ01SaVM4RFhUeXNWeFVTRDdLVERCUHg5eThZc01VLVVPdFlJa1BJczFHX0k4TXJId1lIeWhjNVhwdkVyem1ZRjhuRi1SSGJYV2l6TnhQaC0xSDlZY0tTS2dSeTM5T1BuQWlJUTM0UWIyUVc3SEVsUXM3RmNaNS1zeEZuSV9aVXo0Y1hvVzl3LUs3MmFDZkU3RUFkSG5reDRSUG8waDlSVmdVSkhhbEl3eG9LRWxFX1ZvNkVITV8yWUpHMEFNNkR4Z0800gHwAUFVX3lxTFBUSlVvQVFPbjJ6Z1Q0dWdVdi1jMWpqT3NPX2FZaG52SWhTRGozMHoyWVFZelRwT0ZfakRCamZzXzREWDFqSHkycFp0UURIeEVSUzJBZ1A5Z1pUWEpCbmRfUTRZc2VOTmF1eXZuWFJjZndwdzZ3Skw0bE1qMGVEcHFxQ3d5ZFB5Z2tkZExHMnN2NWZ5SC13NnlxMndUd2l6UkpXblJBNERJSXRxSkdZRTlrM1lLd1lDLXlZcVhCZG80VEtua3VkVktCQ19mVVJHbzNpRm5zc0lvN0k0UkxHREVtWmhNaGxuLS1zNmlNUGl0OA?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis: FDA Label Expansion of Tryngolza Expands Commercial Opportunity; Shares Undervalued", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOWWdUblR3dG5VbUw0WG5oMm1LVU43R2VVc0FnckppR29EM3BORlhid0M1ZUk2VVBUVk83NUt3Sm91QjFVYVVPaFdIdjhfTmtqbjFVU3lpd0pPcDNlTmctdl9tZGpCc2djLW9kRFAwbFlNWVNQeFVmWHhMYXc1WUdVeDJacEVwQWNEci14Y3FCREhSQ01BSWFvYjUwN3l1b3RjbHpXTE93ZS0wWWwtdE9FS0lOaUhVWTRtemd3T1l2c3hCSlAxRUJ4Q0hTcW03U29PcllTTm9qQQ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis hands rare-disease drug zilganersen rights outside the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUzg1VTY4RXJHd2ZfcW4zemxVaHpjSGxlQUplbG9jVm9BSnZUODFUM1QzdmJaVV96RlpzRGpRWWRRZU14aXByaU1VdlRRa3BuQ29NeHhUcHg2NUZtUkw0eTNYdnV0RFNVM24tbHZfTnpWeG1fc2xsYkFtNmppMDRPeXY2eTdKd2U5Tl95SU91YlQ1TXNxSWVTQkRIWkhsRkl1STg3YjhDMVB3aDdNTVVYS3NIUWhmRlVMa2RkNU1kYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ionis Pharmaceuticals (IONS) Trailing US$381.4m Loss Tests Bullish Profitability Narratives Ahead Of Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPLTBvc0tFc003b1I4eGlIaHo5QW05bV85TVVGOGY3Q0djY0FDbDJiMmROZS0yS1Q3YkRaXzFGcG95OC1Ub1Iya1EwNFZyMkU3ZUNqUURidm9hZngycjRjR281M2dIdmFvRmpRZUxtNU1nMnFLR3dTQWtNLWtZREV3VUpVMkNia1ZJZmNQdk00VXdrNGZwd2kzWGZlVEktb1NYa2wwc2V0U1ZSMHNpNDdVUWJkZ2gyRExULWVYSXc2QnJ4M3FGR0FaTGxqTFRmSjIzOEY3TGZ3Q25ETGszc2RrQXJDYnF6Qmo5TElz0gHwAUFVX3lxTE5Idm5pVk5ObVJBbmdrQ1hmRDRkM1Z6YXRjd0wtb0NTOHBZZ2xSN3dKWDlqaGdraHk5WDctSU5abFZta3BDSXVkQXlFVnJRcUhJUmFPNEg1dXZrTjNab25uTi1wV016WlZlajg4a096TTFnS2t4ZFhsNVNvQnFCb2RaQ1VaS05UNzh4M0M2RlV6NlpOOFZ3UzFjcS1Yb0NCOUtrOEJ1WGpZcE03dmVEXzEwazhUSkY2dV9MRlZuRUFkeWVPRFZZdS1venFGMUpndzg0aTAwRVZaREE4Q0tyc2wzREkzdHNMOUV5eVRMZnFEdA?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Ionis Pharmaceuticals (IONS) After A 150% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 58, "sentiment_summary": {"positive": 13, "negative": 18, "neutral": 27, "score": 46, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.0, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.05, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 18}, "market_context": {"has_market_context": true, "latest_close": 54.39, "latest_week": "2026-07-17", "one_week_move": -6.6, "four_week_move": -26.6, "twelve_week_move": -25.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.104386, "market_dynamics_buy_signal": false, "relative_strength": -30.801956, "fair_value_gap": 7.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 56.2814, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.6% over one week, -26.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 9}, {"label": "Market source", "count": 8}, {"label": "Trefis", "count": 5}, {"label": "Business Wire", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 11}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.6% over one week, -26.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Ionis Pharmaceuticals (IONS) Proxy filing Summary"}], "updated_at": "2026-07-19T17:47:28.037742+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}